Skip to main content
. Author manuscript; available in PMC: 2023 Oct 1.
Published in final edited form as: Adv Ther (Weinh). 2022 Aug 4;5(10):2200130. doi: 10.1002/adtp.202200130

Fig 4. Influence of IL-6 on the development of severe CRS.

Fig 4.

(A) Negative correlation between the day of IL-6 reaching peak and initial tumor burden. (B) Negative correlation between the peak IL-6 concentration and the day of IL-6 reaching peak. (C) Variation of the probability of severe CRS as the initial number of B-ALL cells (equivalent to tumor burden) and the release rate of monocytes of IL-6, μM,IL6 change.